Analysis of Molecular Aberrations in Ovarian Cancer Allows Novel Target Identification

Kwai Wa Cheng, John P. Lahad, Gordon B. Mills

    Research output: Contribution to journalArticle

    2 Scopus citations

    Abstract

    The completion of the Human Genome Project and recent advances in functional genomic, proteomic, and high-throughput screening methodologies have provided powerful tools for determining the mechanisms of human diseases, including complex polygenic diseases such as ovarian cancer. These developments may eventually lead to individualized molecular medicine, which is the treatment of patients based on the underlying genetic defects in their tumours and their own genetic makeup. A plethora of novel therapeutic agents that act on specific molecular targets defined by cancer genetics are under development. There is thus a great deal of interest in determining how specific genes and proteins function in cancers, in order to further the understanding of cancer initiation and progression; to aid in identifying biomarkers, therapeutic targets, and determinants of drug responsiveness; and to progress the development of novel antitumour agents.

    Original languageEnglish (US)
    Pages (from-to)461-473
    Number of pages13
    JournalJournal of Obstetrics and Gynaecology Canada
    Volume26
    Issue number5
    DOIs
    StatePublished - Jan 1 2004

    Keywords

    • Genes
    • Microarray
    • Oncogenes
    • Ovarian neoplasms
    • Proteomics
    • Therapeutic target
    • Tumor suppressor

    ASJC Scopus subject areas

    • Obstetrics and Gynecology

    Fingerprint Dive into the research topics of 'Analysis of Molecular Aberrations in Ovarian Cancer Allows Novel Target Identification'. Together they form a unique fingerprint.

  • Cite this